Photo: Gajus /
22 August 2016Americas

Pfizer to acquire Medivation for $14bn

Pfizer has unveiled plans to acquire US based biopharmaceutical company Medivation for approximately $14 billion.

The company is focused on developing and commercialising small molecules for oncology.

Ian Read, CEO of Pfizer, said: “The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer.”

He added: “The addition of Medivation will strengthen Pfizer’s innovative health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over long-term.”

Medivation produces Xtandi (enzalutamide), a prostate cancer treatment, and is also in the process of developing a breast cancer treatment, Talazoparib.

David Hung, CEO of Medivation, said: “We believe the combination with Pfizer is the right next step in our growth trajectory and is a testament to the passion and dedication by which the medication team has delivered on our mission to profoundly transform patients’ lives through medically innovative therapies.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at